The safety and activity of another HSP90 inhibitor, ganetespib (STA-9090), has also been assessed in a heavily pre-treated population with NSCLC in a phase II single arm trial with three cohorts (EGFR+, KRAS+, EGFR/KRAS wild-type) (65). Here, KRAS is linked to non-small cell lung carcinoma.